{"entity":{"id":"src-biocentury","kind":"collection","name":"BioCentury","aka":[],"tldr":"BioCentury writes analysis for people who make decisions about pipelines.","summary":"BioCentury writes strategic analysis of biopharma for people who make decisions about pipelines: regulatory trends, first-in-class approvals, China and deal terms. It publishes daily, and its monthly first-in-class approval tallies and its regulatory reform coverage are distinctive among the industry titles. Access is by subscription, so most of the analysis sits behind a paywall. On OnCo it is listed as a source with the tags source and news, read for the pipeline-level and regulatory view of oncology rather than for individual trial results.","asOf":"2026-09-08","links":[{"label":"BioCentury","url":"https://www.biocentury.com/"}],"tags":["source","news"],"related":["src-evaluate"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.biocentury.com/","holds":"Strategic analysis of biopharma: regulatory trends, first-in-class approvals, China, deal terms.","license":"Subscription","maintainer":"BioCentury Inc."},"route":"/collections/src-biocentury/","neighbours":{"collection":[{"id":"src-endpoints-news","kind":"collection","name":"Endpoints News","route":"/collections/src-endpoints-news/"},{"id":"src-evaluate","kind":"collection","name":"Evaluate Vantage","route":"/collections/src-evaluate/"}]}}